COLL
vs
S&P 500
COLL
S&P 500
Over the past 12 months, COLL has significantly outperformed S&P 500, delivering a return of +38% compared to the S&P 500's +15% growth.
Stocks Performance
COLL vs S&P 500
Performance Gap
COLL vs S&P 500
Performance By Year
COLL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Collegium Pharmaceutical Inc
Glance View
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.